Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases

Diffuse Parenchymal Lung Diseases Clinical Trial

Official title:

Prospective Data Collection of Clinical, Pulmonary Function, Radiological, Bronchoscopic and Fibered Confocal Fluorescence Microscopy Imaging, and Pathological Characteristics in Patients With Diffuse Parenchymal Lung Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01600378
• Other study ID #: 2012/245/Cilddatabase
• Status: Recruiting
• Start date: May 2012
• Est. completion date: December 2030

Study information

• Verified date: April 2024
• Source: Singapore General Hospital
• Contact: Su Ying Low, BMBCh
• Phone: +65 63214700
• Email: low.su.ying[@]singhealth.com.sg
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to generate a prospective database of all patients evaluated for diffuse parenchymal lung diseases to provide much needed data on the various disease aetiologies, incidence and prevalence rates, clinical and radiological presentations, pathologic correlations, disease progression and response to treatment, and final outcomes in this group of patients in Singapore.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 2030
• Est. primary completion date: December 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 90 Years

Eligibility

Inclusion Criteria:

• All patients 21 years old and older diagnosed with suspected diffuse parenchymal lung disease (multi-lobar pulmonary infiltrates)

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Diffuse Parenchymal Lung Diseases
• Lung Diseases
• Lung Diseases, Interstitial

Locations

Country	Name	City	State
Singapore	Singapore General Hospital	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
Singapore General Hospital

Country where clinical trial is conducted

Singapore, 

References & Publications (2)

American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304. doi: 10.1164/ajrccm.165.2.ats01. No abstract available. Erratum In: Am J Respir Crit Care Med2002 Aug 1;166(3):426. — View Citation

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Final diagnoses of patients presenting with diffuse parenchymal lung disease after complete evaluation		3 months